Lilly gains after data for next-generation weight loss drug

Eli Lilly and Co

21/05/2026 16:41

Updates

** Eli Lilly shares LLY.N rise 1.5% to $1,034.69

** Co says obesity patients on the highest dose of its experimental drug retatrutide lost 28.3% of their weight on average over 80 weeks in key trial

** Incidents of dysesthesia, an abnormal skin sensation,  occurred in 5.1%, 12.3%, and 12.5% of patients treated with 4 mg, 9 mg, and 12 mg doses, respectively, compared with 0.9% with placebo

** Discontinuation rates due to adverse events were 4.1%, 6.9%, 11.3%, with 4 mg, 9 mg, and 12 mg doses, respectively, compared with 4.9% with placebo

** The data sets a "new weight loss bar without a major tolerability penalty" - Guggenheim

** "Given retatrutide has reached bariatric level of weightloss, it is likely we have almost reached the pinnacle of what is necessary in terms of efficacy for incretins" - Bernstein

** U.S.-listed shares of rival Novo Nordisk NOVOb.CO down 2%

** LLY shares down 3.5% YTD

 (Reporting by Sriparna Roy in Bengaluru)

 ((Sriparna.Roy@thomsonreuters.com;))